CHICAGO, IL -- February 26, 2007 -- PerkinElmer, Inc. (NYSE: PKI), a global leader in Health Sciences and Photonics, today debuted at PITTCON® 2007, Booth 843, its new PerkinElmer SCIEX™ ELAN® v3.4 software for Inductively Coupled Mass Spectroscopy (ICP-MS) instrumentation.  It has fully automated features to help increase consistency of performance and efficiencies in laboratories with high-productivity demands, including environmental, clinical and geochemical laboratories, and laboratories in the food, nutrition and semiconductor industries.

This new software features enhanced productivity tools such as a new Scheduler feature that allows laboratories to pre-set daily performance checks and to automatically load samples and conduct unattended testing procedures, eliminating the need to manually schedule each test.  Procedures such as auto start and warm-up can be set up to run over night, or early in the morning, resulting in significant time and cost savings for laboratories. Automated tests also help improve data reliability due to the reduction in operator intervention.  

“The ELAN v3.4 reflects what customers asked us for – easy-to-use software that helps them increase throughput in their laboratories, regardless of skill level,” said Ian Shuttler, Ph.D., Inorganic business manager for PerkinElmer Life and Analytical Sciences.  “The automated features enable scientists and researchers to plan the day’s analyses for maximum efficiency and to ensure consistency of performance.”   

The software features enhancements to PerkinElmer’s patented Dynamic Reaction Cell™ (DRC) technology with new fully automated method development optimization that minimizes analysis time for users.  It also simplifies DRC method development by integrating a script, to determine the appropriate testing process. 

Also included is an improved, user-friendly SmartTune feature for unattended multi-parameter optimization of the ICP-MS instrumentation.  A SmartTune window added to the workspace offers improved layout, expanded and improved functionality and more comprehensive and consistent data results.

The ELAN software is compatible with all PerkinElmer ELAN instrumentation and is manufactured through an agreement with MDS SCIEX.

For more information about the ELAN, visit www.perkinelmer.com.

Factors Affecting Future Performance
This press release contains “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements relating to estimates and projections of future earnings per share and revenue growth and other financial results, developments relating to our customers and end-markets, and plans concerning business development opportunities. Words such as “believes,” “intends,” “anticipates,” “plans,” “expects,” “projects,” “forecasts,” “will” and similar expressions, and references to guidance, are intended to identify forward-looking statements.  Such statements are based on management’s current assumptions and expectations and no assurances can be given that our assumptions or expectations will prove to be correct.  A number of important risk factors could cause actual results to differ materially from the results described, implied or projected in any forward-looking statements.  These factors include, without limitation: (1) our failure to introduce new products in a timely manner; (2) our ability to execute acquisitions and license technologies, or to successfully integrate acquired businesses and licensed technologies into our existing business or to make them profitable; (3) our failure to protect adequately our intellectual property; (4) the loss of any of our licenses or licensed rights; (5) our ability to compete effectively; (6) fluctuation in our quarterly operating results and our ability to adjust our operations to address unexpected changes; (7) our ability to produce an adequate quantity of products to meet our customers’ demands; (8) our failure to maintain compliance with applicable government regulations; (9) regulatory changes; (10) economic, political and other risks associated with foreign operations; (11) our ability to retain key personnel; (12) restrictions in our credit agreement; (13) our ability to realize the full value of our intangible assets; and (14) other factors which we describe under the caption “Risk Factors” in our most recent annual report on Form 10-K and in our most recent quarterly report on Form 10-Q and in our other filings with the Securities and Exchange Commission. We disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.

Other Information
Health Sciences end markets include genetic screening, environmental, service, biopharma, and medical imaging.  Photonics markets include sensors and specialty lighting.